Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Jared Haase
Period: Reporting period mapped to calendar 2026 Q3.
- Questions
- 3on tracked calls
- Challenge rate
- 0%none of 3 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 1with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right. See how we grade analysts on earnings-call questions.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 3 of 3 questions from 2 companies
CRLCharles River Laboratories2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2026 Q3
specific workflows that you'd point to that you think can move the needle either financially or operationally
Show response
Girshick cited the automated LAL reagent line adding 14% capacity and Apollo Orchestrate's digitized biologics workflow among 500 ongoing initiatives.
Is that effectively a mechanical relationship where you could sort of benchmark price to a specific measure of inflation
Show response
Girshick said most pricing is negotiated proposal by proposal, with only some clients on rate cards that adjust more automatically.
DGXQuest Diagnostics1 question · 1 reporting period · 0 of 1 challenging
Calendar 2026 Q3
how you think about the growth opportunity for that segment of the market going forward
Show response
The Fresenius dialysis work opened relationships with nephrologists, and a specialized sales force now targets kidney-disease testing for 2027 growth.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| CRL Charles River Laboratories | 2 | —Rate withheld: fewer than 3 questions |
| DGX Quest Diagnostics | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2026 Q3 | 3 | 0%none of 3 questions | 2 |
- 2026 Q33 questions · challenge rate 0% (none of 3 questions) · 2 companies
Topics
Topics tagged on this analyst’s questions.
- Innovation & R&D1
- Margin1
- Pricing1
- Demand1
- Product Launch1